FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/12/1546 |
| _version_ | 1797455777896595456 |
|---|---|
| author | Austin Lui Jordan Vanleuven David Perekopskiy Dewey Liu Desiree Xu Omar Alzayat Taiseer Elgokhy Timothy Do Meghan Gann Ryan Martin Da-Zhi Liu |
| author_facet | Austin Lui Jordan Vanleuven David Perekopskiy Dewey Liu Desiree Xu Omar Alzayat Taiseer Elgokhy Timothy Do Meghan Gann Ryan Martin Da-Zhi Liu |
| author_sort | Austin Lui |
| collection | DOAJ |
| description | Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of <i>both</i> tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments. |
| first_indexed | 2024-03-09T15:59:31Z |
| format | Article |
| id | doaj.art-9b42414dd7eb4fb384afa427d35232f9 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T15:59:31Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-9b42414dd7eb4fb384afa427d35232f92023-11-24T17:17:03ZengMDPI AGPharmaceuticals1424-82472022-12-011512154610.3390/ph15121546FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological DisordersAustin Lui0Jordan Vanleuven1David Perekopskiy2Dewey Liu3Desiree Xu4Omar Alzayat5Taiseer Elgokhy6Timothy Do7Meghan Gann8Ryan Martin9Da-Zhi Liu10Department of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurological Surgery and Neurology, University of California at Davis, Davis, CA 95618, USADepartment of Neurology, University of California at Davis, Davis, CA 95618, USACancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of <i>both</i> tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments.https://www.mdpi.com/1424-8247/15/12/1546aberrant cell cycle diseasecancersneurological disorderskinase inhibitors |
| spellingShingle | Austin Lui Jordan Vanleuven David Perekopskiy Dewey Liu Desiree Xu Omar Alzayat Taiseer Elgokhy Timothy Do Meghan Gann Ryan Martin Da-Zhi Liu FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders Pharmaceuticals aberrant cell cycle disease cancers neurological disorders kinase inhibitors |
| title | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
| title_full | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
| title_fullStr | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
| title_full_unstemmed | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
| title_short | FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders |
| title_sort | fda approved kinase inhibitors in preclinical and clinical trials for neurological disorders |
| topic | aberrant cell cycle disease cancers neurological disorders kinase inhibitors |
| url | https://www.mdpi.com/1424-8247/15/12/1546 |
| work_keys_str_mv | AT austinlui fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT jordanvanleuven fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT davidperekopskiy fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT deweyliu fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT desireexu fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT omaralzayat fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT taiseerelgokhy fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT timothydo fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT meghangann fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT ryanmartin fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders AT dazhiliu fdaapprovedkinaseinhibitorsinpreclinicalandclinicaltrialsforneurologicaldisorders |